68Ga-SSO-120 PET 用于小细胞肺癌患者初始分期:单中心回顾性研究
该单中心回顾性研究纳入31例新诊断小细胞肺癌患者,在初始诊断流程中加做全身68Ga-SSO-120 PET/CT,并与18F-FDG PET/CT对比。结果显示68Ga-SSO-120在所有患者中均检出肿瘤,检出率与18F-FDG PET相当,并可提供补充信息,多数患者摄取一致,值得探索SSTR2靶向放射性核素治疗。
要点
- 68Ga-SSO-120 PET在所有31例患者中检出肿瘤,区域检出率为41.5%。
- 在25例可评估18F-FDG PET的患者中,两者对原发灶、胸部淋巴结及远处转移的检出率相近。
- 68Ga-SSO-120 PET可补充检出对侧淋巴结、肝及脑转移,但未改变VALSG分期。
核心结论
- 68Ga-SSO-120 PET诊断精度高,检出率与金标准18F-FDG PET相当,并提供补充信息。
- 多数患者摄取一致,值得探索SSTR2靶向放射性核素治疗。
研究设计与样本
- 单中心回顾性研究,回顾性纳入新诊断小细胞肺癌并在初始诊断流程中加做全身68Ga-SSO-120 PET/CT的患者。
- 共纳入31例患者,其中局限期12例、广泛期19例(VALSG分类)。
- 平均给药活度为139 MBq,平均摄取时间为60 min。
- 以临床肿瘤委员会共识TNM分期(基于CT、EBUS-TBNA、PET和脑MRI)为参考标准。
- 若18F-FDG PET/CT在68Ga-SSO-120 PET前后2周内且CT形态学无差异,则作为金标准分期进行评估。
主要发现
- 68Ga-SSO-120在全部31例患者中检出阳性肿瘤(100%),在217个可评估区域中检出90个(41.5%)。
- 13例患者(42.0%)平均68Ga-SSO-120摄取强烈(区域平均SUVmax ≥ 10)。
- 28例患者(90.3%)平均68Ga-SSO-120摄取高于肝脏摄取(区域平均肿瘤/肝脏峰值比 > 1)。
- 在25例可评估18F-FDG PET的患者中,68Ga-SSO-120对原发灶、胸部淋巴结转移和远处转移的检出率分别为100%、92%和64%,18F-FDG PET分别为100%、92%和56%。
- 68Ga-SSO-120 PET额外检出对侧淋巴结、肝和脑转移各1、1和2例(无组织病理学),18F-FDG PET额外检出对侧淋巴结转移3例(1例确认、1例系统EBUS-TBNA阴性、1例无组织病理学)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PET imaging using the somatostatin receptor 2 (SSTR2) antagonist satoreotide trizoxetan (SSO-120, previously OPS-202) could offer accurate tumor detection and screening for SSTR2-antagonist radionuclide therapy in patients with SSTR2-expressing small cell lung cancer (SCLC). The aim of this single-center study was to investigate tumor uptake and detection rates of 68Ga-SSO-120 in comparison to 18F-FDG PET in the initial staging of SCLC patients. Methods: Patients with newly diagnosed SCLC who underwent additional whole-body 68Ga-SSO-120 PET/CT during the initial diagnostic workup were retrospectively included. The mean administered activity was 139 MBq, and the mean uptake time was 60 min. Gold-standard staging 18F-FDG PET/CT was evaluated if available within 2 wk before or after 68Ga-SSO-120 PET if morphologic differences in CT images were absent. 68Ga-SSO-120- or 18F-FDG-positive lesions were reported in 7 anatomic regions (primary tumor, thoracic lymph node metastases, and distant metastases including pleural, contralateral pulmonary, liver, bone, and other) according to the TNM classification for lung cancer (eighth edition). Consensus TNM staging (derived from CT, endobronchial ultrasound-guided transbronchial needle aspiration, PET, and brain MRI) by a clinical tumor board served as the reference standard. Results: Thirty-one patients were included, 12 with limited and 19 with extensive disease according to the Veterans Administration Lung Study Group classification. 68Ga-SSO-120-positive tumor was detected in all patients (100%) and in 90 of the 217 evaluated regions (41.5%). Thirteen patients (42.0%) had intense average 68Ga-SSO-120 uptake (region-based mean SUVmax ≥ 10); 28 patients (90.3%) had average 68Ga-SSO-120 uptake greater than liver uptake (region-based mean peak tumor-to-liver ratio > 1). In 25 patients with evaluable 18F-FDG PET, primary tumor, thoracic lymph node metastases, and distant metastases were detected in 100%, 92%, and 64%, respectively, of all investigated patients by 68Ga-SSO-120 and in 100%, 92%, and 56%, respectively, by 18F-FDG PET. 68Ga-SSO-120 PET detected additional contralateral lymph node, liver, and brain metastases in 1, 1, and 2 patients, respectively (no histopathology available), and 18F-FDG PET detected additional contralateral lymph node metastases in 3 patients (1 confirmed, 1 systematic endobronchial ultrasound-guided transbronchial needle aspiration-negative, and 1 without available histopathology). None of these differences altered Veterans Administration Lung Study Group staging. The region-based monotonic correlation between 68Ga-SSO-120 and 18F-FDG uptake was low (Spearman ρ = 0.26-0.33). Conclusion: 68Ga-SSO-120 PET offers high diagnostic precision with comparable detection rates and additional complementary information to the gold standard, 18F-FDG PET. Consistent uptake in most patients warrants exploration of SSTR2-directed radionuclide therapy.
引用
- Kersting D, Sandach P, Sraieb M, et al. 68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study. J Nucl Med. 2023. PMID: 37474272. doi:10.2967/jnumed.123.265664
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。